Literature DB >> 2139575

High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.

H W van den Berg1, J Martin, M Lynch.   

Abstract

Culture of ZR-75-1 human breast cancer cells for 5 days in the absence of oestrogens (phenol red-free medium supplemented with dextran coated charcoal stripped 5% fetal calf serum) resulted in a slowing of growth rate and loss of progesterone receptors. Oestradiol at 10(-9) M markedly stimulated growth and progesterone receptor synthesis over a 5-day period. While medroxyprogesterone acetate (10(-10) to 10(-6) M) inhibited growth of ZR-75-1 cells growing in complete medium, in the short-term absence of oestrogens low concentrations were growth stimulatory. Cells deprived of oestrogens for 5 days retained sensitivity to growth inhibition by 4-hydroxy tamoxifen. ZR-75-1 cells were also adapted to growth in the absence of oestrogens over a 5-month period. These cells (ZR-PR-LT) failed to express binding sites characteristic of the type 1 oestrogen receptor but progesterone receptor expression was at a level normally associated with oestrogen induction. Adapted cells were growth inhibited by oestradiol, 4-hydroxy tamoxifen and medroxyprogesterone acetate, but despite elevated progesterone receptor expression the progestin was only marginally more inhibitory than in the parent line. Our data indicate a poor quantitative relationship between response to progestins in vitro and progesterone receptor concentration and support previous findings that acquisition of an oestrogen independent phenotype does not necessarily result in resistance to anti-oestrogens.

Entities:  

Keywords:  Biology; Breast Cancer; Cancer; Clinical Research; Contraception; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Diseases; Endocrine System; Estrogens--pharmacodynamics; Family Planning; Fertility Agents; Hormone Receptors; Hormones; In Vitro; Medroxyprogesterone Acetate--pharmacodynamics; Membrane Proteins; Neoplasms; Physiology; Progestational Hormones; Progesterone--pharmacodynamics; Reproductive Control Agents; Research Methodology; Tamoxifen--pharmacodynamics; Treatment

Mesh:

Substances:

Year:  1990        PMID: 2139575      PMCID: PMC1971370          DOI: 10.1038/bjc.1990.114

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Effects of progestins on growth of experimental breast cancer in culture: interaction with estradiol and prolactin and involvement of the polyamine pathway.

Authors:  A Manni; B Badger; C Wright; S R Ahmed; L M Demers
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

2.  The presence of a second, specific estrogen binding site in human breast cancer.

Authors:  W B Panko; C S Watson; J H Clark
Journal:  J Steroid Biochem       Date:  1981-12       Impact factor: 4.292

3.  Progestin effects on growth in the human breast cancer cell line T-47D--possible therapeutic implications.

Authors:  J R Hissom; M R Moore
Journal:  Biochem Biophys Res Commun       Date:  1987-06-15       Impact factor: 3.575

4.  Conformational transitions of the estrogen receptor monomer. Effects of estrogens, antiestrogen, and temperature.

Authors:  J C Hansen; J Gorski
Journal:  J Biol Chem       Date:  1986-10-25       Impact factor: 5.157

5.  Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens.

Authors:  B S Katzenellenbogen; K L Kendra; M J Norman; Y Berthois
Journal:  Cancer Res       Date:  1987-08-15       Impact factor: 12.701

6.  Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018.

Authors:  D A Bronzert; G L Greene; M E Lippman
Journal:  Endocrinology       Date:  1985-10       Impact factor: 4.736

7.  Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture.

Authors:  Y Berthois; J A Katzenellenbogen; B S Katzenellenbogen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

Review 8.  Progesterone receptors and human breast cancer.

Authors:  G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

9.  Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance.

Authors:  K B Horwitz; M B Mockus; B A Lessey
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

10.  Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen.

Authors:  H W van den Berg; W J Leahey; M Lynch; R Clarke; J Nelson
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

View more
  3 in total

1.  Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line.

Authors:  B Long; B M McKibben; M Lynch; H W van den Berg
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

2.  Experimental models of endocrine responsive breast cancer: strengths, limitations, and use.

Authors:  Robert Clarke; Brandon C Jones; Catherine M Sevigny; Leena A Hilakivi-Clarke; Surojeet Sengupta
Journal:  Cancer Drug Resist       Date:  2021-07-08

3.  Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression.

Authors:  H W van den Berg; D Claffie; M Boylan; J McKillen; M Lynch; B McKibben
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.